Kyowa Kirin Co., Ltd. · TSE:4151

Kyowa Kirin — Kyowa Hakko Kirin — FY2009 Earnings Presentation

29 slides from Kyowa Kirin's earnings presentation, Jan 29, 2010

  1. Slide 1: Fiscal 2009 Results (Nine-month period April-December 2009)

    Kyowa Kyowa Hakko Hakko Kirin Kirin Fiscal Fiscal 2009 2009 Results Results (Nine-month period (Nine-month periodApril-December 2009 April-December ） 2009） January 29, 2010 President & CEO Yuzuru Matsuda Kyowa Hakko Kirin Co., Ltd Statements on results, forecasts and R&D status contained in this pre

  2. Slide 2: Contents

    Contents Page >> Summary of fiscal 2009 results 2 >> Pipeline 13 >> Fiscal 2010 forecasts 21 >> Appendix 28 1

  3. Slide 3: Summary of fiscal 2009 results

    Summary of fiscal 2009 results 2

  4. Slide 4: Summary of fiscal 2009 results: P&L

     Summary of fiscal 2009 results: P&L Operating Recurring (¥bn) Net sales Net income income income FY2009 309.1 28.2 29.4 8.7 (Apr.-Dec.) -53.1 -14.4 -13.7 -1.6 Change (-14.7%) (-33.8%) (-31.9%) (-16.1%) FY2008 362.2 42.6 43.2 10.4 (Apr.-Dec.) Summary Sales and profits decreased due to the exclusion

  5. Slide 5: Summary of fiscal 2009 results: Pharmaceuticals business

     Summary of fiscal 2009 results: Pharmaceuticals business (¥bn) FY2008 FY2009 Change (Apr.-Dec.) (Apr.-Dec.) Net sales 161.3 158.2 -3.0 Operating income 29.6 26.6 -3.0 R&D expenses 32.5 31.6 -0.9 Apr. to Dec. 2008 2009 Forex ¥103/$ ¥94/$ Excluding the one-time effects of the out-licensing income re

  6. Slide 6: Sales of core pharmaceutical products – non-consolidated

     Sales of core pharmaceutical products – non-consolidated FY2008 FY2009 (¥bn) Change (Apr.-Dec.) (Apr.-Dec.) Nesp/Espo 34.4 39.6 15%↑ Coniel 18.1 18.3 1%↑ Allelock 15.6 17.3 11%↑ Patanol 2.2 3.0 36%↑ Gran/Neu-up 14.3 13.8 3%↓ Depakene 8.3 8.8 6%↑ Coversyl 4.0 3.7 8%↓ Regpara 3.3 5.5 67%↑ Export and

  7. Slide 7: Summary of fiscal 2009 results: Bio-Chemicals and Chemicals businesses

     Summary of fiscal 2009 results: Bio-Chemicals and Chemicals businesses FY2008 FY2009 Change (¥bn) (Apr.-Dec.) (Apr.-Dec.) Net sales 67.5 69.7 +2.2 Bio-Chemicals Operating income 7.4 3.0 -4.3 Net sales 77.3 52.3 -24.9 Chemicals Operating income 3.5 -1.9 -5.5 ¥/$ ¥103/$ ¥94$ -¥9/$ Forex ¥/€ ¥151/€ ¥

  8. Slide 8: Chemicals business

     Chemicals business (¥bn) Net sales Operating income Naphtha (K/L) 40.0 32.0 \85,800 30.0 20.1 19.4 20.0 17.8 15.0 \42,600 \52,000 11.8 \41,300 10.0 \33,300 2.4 \27,000 0.5 0.5 0.0 -2.0 -0.4 -3.5 -10.0 08/7-9 08/10-12 09/1-3 09/4-6 09/7-9 09/10-12 The price of naphtha (the index price for raw mater

  9. Slide 9: Pipeline

    KYOWA KIRIN Pipeline copyright© Kyowa Hakko Kirin Co.,Ltd. All Rights mm °)

  10. Slide 10: R&D Pipeline

     R&D Pipeline Phase II, Phase III (As of January 2010) Stage Code name/ Category Other Indication Formulation In-house or licensed Remarks Product name Japan countries Humanized monoclonal antibody Phase Ⅰ/Ⅱa Cancer (The exclusive right to develop and commercialize for KW-0761 Phase Ⅱ in USA (Hemat

  11. Slide 11: R&D Pipeline (continued)

     R&D Pipeline (continued) Phase II, Phase III (As of January 2010) Stage Code name/ Category Indication Formulation In-house or licensed Remarks Product name Japan Other countries Filed in USA KW-6002 Phase III Parkinson's disease Oral In-house Apr/2007 CNS Licensed from KW-6500 Phase III Parkinson

  12. Slide 12: R&D Pipeline (continued)

     R&D Pipeline (continued) Phase I (As of January 2010) Stage Code name/ Category Other Indication Formulation In-house or licensed Remarks Product name Japan countries Fully human monoclonal Immunology/ antibody ASKP1240 Phase I Organ Transplant Rejection Injection In-house Allergy Developed with A

  13. Slide 13: Antibody pharmaceutical pipeline (as of January 2010)

     Antibody pharmaceutical pipeline (as ( of January 2010) Overview of Development Pipeline Therapeutic Preclinical Ph I Ph II Area KW-0761 (CCR4) U.S. (Ph I/IIa) Japan (Ph II) KRN330(A33) Cancer Ten Antibodies U.S. (Ph I/IIa) (eight BIW-8962 (GM2) POTELLIGENT® U.S. (Ph I/IIa) antibodies, five KM-Mou

  14. Slide 14: Licensed-out antibody pharmaceuticals

     Licensed-out antibody pharmaceuticals (as of January 2010) Antibody Target Licensee Reported Stage Remarks Amgen Ph I KW-0761 CCR4 POTELLIGENT® (Except in JP, CN, KR,TW) (AMG 761) MedImmune Ph II BIW-8405 IL-5R POTELLIGENT® (Except in Japan, Asia) (MEDI-563） Life Science KW-2871 GD3 Ph II Pharmace

  15. Slide 15: POTELLIGENT technology related alliances

    POTELLIGENT® technology related alliances (as of January 2010) Product Licenses Joint R&D In-license Out-license Technology Licenses CSL Limited *Clinical trials are in progress for five out-licensed POTELLIGENT antibodies 14

  16. Slide 16: Progress in licensed-out compounds-1

     Progress in licensed-out compounds-1 (as of January 2010) Phase Name Partner Remarks I II III Merck KW-3902 Terminated (NovaCardia) Myeloproliferative disorders CEP-701 Cephalon (FLT-3 inhibitor) Cancer KW-2871 Life Science (anti-GD3) (Low-fucose antibody) (malignant melanoma) MEDI-563 Allergy Med

  17. Slide 17: Progress in licensed-out compounds-2

     Progress in licensed our compounds -2 (as of January 2010) Phase Name Partner Remarks I II III Inflammatory bowel disease Zeria (Crohn’s disease) Asacol Pharmaceutical *Application filed for ulcerative colitis Parkinson’s disease KW-6500 Britannia (injection) ARQ197 ArQule Cancer Hisamitsu HFT-290

  18. Slide 18: Update on licensing-in contracts

     Update on licensing-in contracts Dec. 24, 2009 Immunas Pharma, Inc. (Japan) Acquisition of exclusive implementation rights to ANTIAMYLOID ß PEPTIDE ANTIBODY January 4, Dicerna Pharmaceuticals, Inc. (USA) 2010 Joint research on DDS technology for nucleic acid pharmaceuticals and acquisition of comm

  19. Slide 19: Reata Pharmaceuticals, Inc.

     Reata Pharmaceuticals, Inc. Reata Pharmaceuticals, Inc. http://www.reatapharma.com/ Established: 2002 Location: Irving, Texas, USA CEO: Warren Huff Business: Development of anti-inflammatory drugs Bardoxolone methyl A low molecular weight pharmaceutical targeting diabetic patients with chronic kid

  20. Slide 20: Fiscal 2010 forecasts

    KYOWA KIRIN Fiscal 2010 forecasts

  21. Slide 21: Fiscal 2010 full year forecasts

     Fiscal 2010 full year forecasts Operating Recurring Net (¥bn) Net sales income income income 2010 (Jan.-Dec.) 400.0 36.0 37.5 20.0 vs. 2009 (Jan.-Dec.) (-1.7%) (+16.4%) (+14.9%) (+99.2%) 2009 (Jan.-Dec.) 407.0 30.9 32.6 10.0 Note: Fiscal 2009 was a nine-month period due to a change in fiscal year

  22. Slide 22: Fiscal 2010 full year forecasts: Pharmaceuticals

     Fiscal 2010 full year forecasts: Pharmaceuticals (¥bn) 2009 2010 Change (Jan.-Dec.) (Jan.-Dec.) Net sales 207.3 205.0 -2.3 Operating income 31.8 29.0 -2.8 R&D expenses 41.6 41.5 -0.1 >> Net sales - Although price revisions are expected to result in a decline in sales, sales of core products are ex

  23. Slide 23: Fiscal 2010 full year forecasts: products

    Sales of core pharmac  Fiscal 2010 full year forecasts: products eutical pharmaceutical (non consolidated) (¥bn) 2009 2010 % change (Jan.-Dec.) (Jan.-Dec.) Nesp/Espo 48.9 49.7 2%↑ Coniel 23.3 21.3 9%↓ Allelock 26.7 26.0 3%↓ Patanol 7.4 7.9 7%↑ Gran/Neu-up* 17.0 15.1 11%↓ Depakene 11.2 11.0 2% ↓ Cov

  24. Slide 24: Fiscal 2010 forecasts: Bio-Chemicals/Chemicals

     Fiscal 2010 forecasts: Bio-Chemicals/ Chemicals 2009 2010 (¥bn) Change (Jan.-Dec.) (Jan.-Dec.) Bio- Sales 90.6 84.0 -6.6 Chemicals Operating income 3.9 4.0 +0 Sales 64.2 121.0 +56.7 Chemicals Operating income (5.5) 2.7 +8.2 ¥/$ ¥94/$ ¥91/$ -¥3/$ Forex ¥/€ ¥130/€ ¥133/€ +¥3/€ Approx. Approx. Approx

  25. Slide 25: Appendix

    KYOWA KIRIN Appendix copyright© Kyowa Hakko Kirin Co.,Ltd. All Rights mm’)

  26. Slide 26: Pharmaceuticals: Major factors affecting results

     Pharmaceuticals: Major factors affecting results All listed factors are on a non-consolidated basis unless stated otherwise Fiscal 2008 Net sales Fiscal 2009 (Apr.- Dec.) (Apr.- Dec.) ¥161.3 bn -¥3.0 bn ¥158.2 bn Positive factors Growth in sales of core products Negative factors One-time contract

  27. Slide 27: Bio-Chemicals: Major factors affecting results

     Bio-Chemicals: Major factors affecting results All listed factors are on a non-consolidated basis unless stated otherwise Fiscal 2008 Net sales Fiscal 2009 (Apr.- Dec.) (Apr.- Dec.) ¥67.5 bn +¥2.2 bn ¥69.7 bn Positive factors Consolidation of 12-month results of overseas subsidiaries following cha

  28. Slide 28: Chemicals: Major factors affecting results

     Chemicals: Major factors affecting results All listed factors are on a non-consolidated basis unless stated otherwise Fiscal 2008 Net sales Fiscal 2009 (Apr.- Dec.) (Apr.- Dec.) ¥77.3 bn -¥24.9 bn ¥52.3 bn Positive factors Expanded sales of functional products Negative factors Reduced demand due t

  29. Slide 29: Inquiries: Corporate Communications Department

    If you have any inquiries regarding this presentation please call: Corporate Communications Department, Kyowa Hakko Kirin Co., Ltd Tel: 03-3282-0009 28

Kyowa Hakko Kirin — FY2009 Earnings Presentation on 6ix